OSSFF (Embla Medical hf) Financial Strength: 5 (As of Mar. 2026) — 17% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSSFF Embla Medical hf OSSFF
91 GF Score
Price $4.15
GF Value $5.43
! 2 Warning Signs
View Full Analysis

What is Embla Medical hf Financial Strength?

Embla Medical hf OSSFF 91 Financial Strength is 5 as of Mar. 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates OSSFF with a GF Score™ of 91/100 and a GF Value™ of $5.43. The stock has 2 warning signs investors should review.

Embla Medical hf has the Financial Strength Rank of 5.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is rated on a scale of 1 to 10 and is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.
4. Other debt related ratios.

A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Embla Medical hf's Interest Coverage for the quarter that ended in Mar. 2026 was 4.65. Embla Medical hf's debt to revenue ratio for the quarter that ended in Mar. 2026 was 0.59. As of today, Embla Medical hf's Altman Z-Score is 2.87.


Embla Medical hf  (OTCPK:OSSFF) Financial Strength Explanation

The rank is rated on a scale of 1 to 10. A higher score indicates a stronger financial position, with companies rated 7 or above considered financially stable and unlikely to face distress. Conversely, a score of 3 or below suggests potential financial difficulties, indicating a higher risk of distress.

Embla Medical hf has the Financial Strength Rank of 5.


Embla Medical hf Financial Strength Related Terms


OSSFF vs ABT, SYK, MDT: Financial Strength Comparison

For the Medical Devices subindustry, Embla Medical hf's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Embla Medical hf Financial Strength vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Financial Strength distribution charts can be found below:

* The bar in red indicates where Embla Medical hf's Financial Strength falls into.


OSSFF
91GF Score
Embla Medical hf OSSFF
Financial Strength is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Embla Medical hf Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Embla Medical hf's Interest Expense for the months ended in Mar. 2026 was $-4.9 Mil. Its Operating Income for the months ended in Mar. 2026 was $22.6 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $363.7 Mil.

Embla Medical hf's Interest Coverage for the quarter that ended in Mar. 2026 is

Interest Coverage=-1*Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*22.64/-4.864
=4.65

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Embla Medical hf's Debt to Revenue Ratio for the quarter that ended in Mar. 2026 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2026 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(189.245 + 363.694) / 929.58
=0.59

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Embla Medical hf has a Z-score of 2.87, indicating it is in Grey Zones. This implies that Embla Medical hf is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.87 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Financial Strength →
What does a Financial Strength of 5 mean?
Embla Medical hf (OSSFF) has a Financial Strength of 5 as of Mar. 2026. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Embla Medical hf and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Embla Medical hf's Financial Strength has ranged from 4.00 to 7.00.
Is Embla Medical hf's Financial Strength too high?
Embla Medical hf's current Financial Strength of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 7.00. Overall, Embla Medical hf has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Financial Strength compare to ABT and SYK?
Embla Medical hf's Financial Strength of 5 can be compared against companies in the Medical Devices & Instruments industry. Historically, Embla Medical hf's own Financial Strength has ranged from 4.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Financial Strength for a Medical Devices & Instruments company?
A good Financial Strength depends on the Medical Devices & Instruments industry context. However, Financial Strength should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Financial Strength mean?
A high Financial Strength can signal that a stock is expensive relative to its fundamentals. The financial strength rank measures the strength of a company's balance sheet based on revenue and debt. View historical data on Embla Medical hf and its competitors. Embla Medical hf's current Financial Strength is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Embla Medical hf (OSSFF) has a current Financial Strength of 5. The stock's GF Value™ is $5.43, compared to a current price of $4.15 — trading 23.6% below its estimated fair value. The current Financial Strength is 5, which is 17% below median its 10-year median of 6.00. Embla Medical hf's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Financial Strength calculated?
Financial Strength is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current Financial Strength is 5 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embla Medical hf (OSSFF) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of $4.15 is trading 23.6% below its estimated GF Value™ of $5.43.

Key valuation signals for OSSFF:

  • Financial Strength: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: $5.43 vs. price of $4.15 (23.6% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Embla Medical hf Business Description

Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
91GF Score

Get the complete analysis for OSSFF

Financial Strength is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.15
Price
$5.43
GF Value